Introduction {#s1}
============

The average heart beats over a billion times during one lifespan to continuously provide blood to every part of the body. Crucial to this task are the four heart valves (aortic, pulmonic, tricuspid and mitral) that function to maintain the unidirectional blood flow. Distinct from the cardiac muscle, the mature valve leaflets are highly organized structures comprised of three layers of extracellular matrix (ECM) components including collagens, proteoglycans, and elastin ([@B1]). Formation and maintenance of the valve ECM is mediated by a heterogeneous population of valve interstitial cells (VICs) that are fibroblast-like in phenotype ([@B2]). Surrounding the VICs and ECM is a single layer of valve endothelial cells (VECs) that physically protect the valve from external stimuli, and molecularly communicate with underlying VICs to regulate homeostasis of the ECM ([@B3]--[@B5]). The complex relationship between valve cell populations and the ECM is critical for establishing and maintaining structure-function relationships throughout life. This relationship begins during embryonic development, as mesenchymal precursor cells in the endocardial cushions transition towards an activated VIC phenotype and degrade primitive ECM within the cushions while secreting more diverse ECM components. Elongation and remodeling of the immature valve structures continues for a short time during the postnatal period until around day 10 in the mouse when the ECM components are more defined. Once valve formation is complete, VICs convert to a quiescent phenotype and in the absence of disease, maintain physiological turnover of the ECM to provide efficient function throughout life \[reviewed ([@B2],[@B6])\]. While the regulation of valve development is well established, the mechanisms that regulate postnatal valve growth and remodeling, as well as adult homeostasis are poorly understood. Despite constant mechanical demand on the valve leaflets, turnover of valve cell populations in adult valves is relatively low ([@B4]). Therefore, it remains unclear how valve cell populations and structure-function relationships are maintained throughout life in healthy individuals, yet dysregulation of these relationships likely underlie the onset and progression of valve dysfunction and disease.

Heart valve disease is a growing public health problem that can affect both adult and pediatric patients. Significant defects during embryonic valve development lead to congenital malformations which compromise the typical structure of the valve, often resulting in reduced ability to function correctly \[reviewed ([@B7])\]. Distinct from valve disease present at birth, pathology can also be acquired and is most prevalent in the aging population, with up to 13% of people aged over 75 affected by diseases including calcification or myxomatous degeneration ([@B8]). Currently, the only effective treatment for valve disease is surgical repair or replacement, resulting in over 90,000 valve replacement surgeries performed in the US each year ([@B9]). Surgical treatment comes with many complications including the need for repeat surgeries due to low valve durability and high thrombogenicity, in addition to the large personal and societal economic burdens ([@B10]). Therefore, there is a critical need for the development of alternate therapeutics.

A promising therapeutic area is emerging in the field of self-repair and regenerative medicine. Common to both congenital and age-related valve disease is the damage and consequent loss of healthy cell populations alongside the development of pathological cell populations that are therefore unable to preserve valve structure-function relationships ([@B11]). The field of cardiac regeneration has recently made significant advances in elucidating the molecular mechanisms of regeneration, and it has been reported that the neonatal myocardium has remarkable regenerative capacity during the first seven days of life ([@B12]--[@B14]). Furthermore, several pathways have been identified as key players, and the ability to recapitulate these neonatal programs in adults has proven successful in promoting myocardial regeneration after injury and in disease models ([@B15]--[@B18]).

Neonatal, adult and potential regenerative programs have not been examined in heart valves and therefore the goal of this current study is to initiate this discovery. To do this, we used RNA-seq analysis to explore differential molecular profiles between postnatal and adult valve cell populations. This analysis will help define potential regeneration indicators that in the future might be reintroduced in diseased or aging adult valves to increase their self-repair capacity and improve structure-function relationships. Our study has defined transcriptional differences between postnatal day 2 (PND2) and adult (4 months) aortic valves and identified significant changes in key biological functions related to cell proliferation, ECM, and defense response that may be important for determining the regenerative capacity of the valve to aid in the future development of alternative therapeutics.

Material and Methods {#s2}
====================

Mice {#s2-1}
----

*C57BL/6J* mice were fed regular chow mix and housed in a controlled environment with 12 h light/dark cycles at 21°C and 23% humidity and water ad libitum. Animals were euthanized by CO~2~ exposure followed by secondary euthanasia by cervical dislocation (adult mice) or decapitation (pups). All animal procedures were approved by The Research Institute at Nationwide Children's Hospital Institutional Animal Care and Use Committee (Protocol \# AR13-00054).

Tissue Preparation {#s2-2}
------------------

Hearts were collected from postnatal day 2 (PND2) and 4 month old *C57BL/6J* mice and fixed in 4% paraformaldehyde/1xPBS overnight at 4°C. For paraffin sections, tissue was embedded in paraffin wax and sectioned at 10 µm. Paraffin was removed in xylene, and tissue sections were re-hydrated through a graded ethanol series and rinsed in 1xPBS as previously described ([@B19]). Tissue sections containing aortic valves were then subjected to Movat's Pentachrome staining, EdU staining, or immunohistochemistry/immunofluorescence (described below). For cryo sections, tissue was embedded in OCT and frozen, then sectioned at 7 µm. Prior to staining, tissue was permeabilized using 0.1% Triton-X 100 in 1xPBS and then subjected to immunofluorescence staining.

Immunohistochemistry/Immunofluorescence {#s2-3}
---------------------------------------

Whole hearts from PND2 and 4 month old *C57BL/6J* mice were collected and prepared according to above methods. Movat's Pentachrome staining was performed on paraffin tissue sections at each time point according to the manufacturer's instructions (Russel Movat, American MasterTech, \#KTRMP), then mounted using VectaMount Permanent Mounting Medium (Vector Laboratories, H-5000). For antibody detection, fixed paraffin tissue sections were subjected to antigen retrieval by boiling for 10 min in unmasking solution (Vector Laboratories), and both cryo and paraffin sections were subjected to blocking for 1 h at room temperature (1% BSA, 1% cold water fish skin gelatin, 0.1% Tween-20/PBS) as described ([@B20]). Tissue sections were then incubated overnight at 4°C or 1 h at room temperature with primary antibodies against Mmp3 (rabbit, 1:100 paraffin, Abcam ab53015), Nid2 (rabbit, 1:200 cryo, Abcam ab14513), Ptgs2 (Rabbit, 1:100 paraffin, Cell Signaling 12282), and Rarres2 (Mouse, 1:100 paraffin, Santa Cruz sc-373797). For immunofluorescent primary antibody detection of Mmp3, Nid2, and Ptgs2, sections were incubated for 1 h at room temperature with Donkey anti-rabbit or Goat anti-rabbit Alexa-Fluor IgG secondary antibodies (1:500) (LifeTechnologies), then mounted in Vectashield anti-fade medium with DAPI (Vector Laboratories) to detect cell nuclei. For diaminobenzidine (DAB) staining of Rarres2, sections were stained using Mouse and Rabbit Specific HRP/DAB (ABC) Detection IHC kit (Abcam, ab64264), counterstained with hematoxylin (Vector Laboratories, H-3404), and mounted using VectaMount Permanent mounting medium (Vector Laboratories, H-5000). Images were visualized using an Olympus BX51 microscope and captured using an Olympus DP71 camera and CellSens software. Image brightness and contrast were edited using Adobe Photoshop CC.

EdU Staining and Quantification {#s2-4}
-------------------------------

PND2 and 4 month old *C57BL/6J* mice were injected subcutaneously with 10 µg/g body weight EdU (Invitrogen) dissolved in 1xPBS. 24 h later, mice were sacrificed and hearts were collected and prepared according to above methods. Fixed tissue sections were blocked for 1 h at room temperature (1% BSA, 0.1% Cold water fish skin gelatin, 0.1% Tween 20 in PBS with 0.05% NaN~3~), followed by use of Click-it EdU Kit (Invitrogen) to detect presence of EdU according to the manufacturer's instructions. Sections were then mounted in Vectashield anti-fade medium with DAPI (Vector Laboratories) to detect cell nuclei. The total number of cell nuclei in one leaflet were counted using ImageJ cell counter. The number of EdU + cells were then counted and calculated as a percentage of total cells. An average of 9 leaflets were counted and averaged for each mouse, with a total *n* = 3. Statistical analysis was performed in GraphPad Prism 7.0a.

Aortic Valve Isolation and RNA-Sequencing {#s2-5}
-----------------------------------------

Aortic valves from wild type PND2 and 4 month old *C57BL/6J* mice were isolated with minimal myocardial contamination and immediately flash frozen in liquid nitrogen. Frozen samples were sent to Ocean Ridge Biosciences LLC (Deerfield Beach, FL), where RNA isolation and sequencing was performed as follows. Total RNA was extracted using the TRI Reagent® (Molecular Research Center; Part \#: TR118) method, and isolated RNA was quantified using chip-based capillary electrophoresis (Agilent 2100 Bioanalyzer Pico Chip). RNA was digested with RNase free DNase I (Epicentre; Part \# D9905K) and purified through minElute columns (Qiagen; Part \#: 74204). Final RNA samples were quantified by O.D. measurement and re-quantified using chip-based capillary electrophoresis. Amplified cDNA libraries were prepared from 200 ng on DNA-free total RNA using TruSeq Stranded Total mRNA Library Prep Kit LT (Illumina Inc.; Part \#s: RS-122-2101 and RS-122-2102). Chip-based capillary electrophoresis was used to assess quality and size distribution of the libraries. KAPA Library Quantification Kit (Kapa Biosystems, Boston, MA) was used to quantify the libraries. Libraries were pooled at equimolar concentrations and were clustered on an illumina cBot cluster station. Clustering was performed with the HiSeq PE cluster kit v4 and sequenced on an Illumina HiSeq Flow Cell v4 with 50 nt paired-end reads plus dual index reads using the Illumina HiSeq SBS Kit v4. An average of approximately 48.3 million passed-filter 50 nucleotide paired-end reads were obtained per sample (24.1M per direction).

Raw FASTQs were split into files containing 4,000,000 reads and checked for quality using the FASTX-Toolkit. The reads were filtered (removing sequences that did not pass Illumina's quality filter) and trimmed based on the quality results (3 nucleotides at the left end of the R1 reads and 1 nt at the left end of the R2 reads). Sequence alignment was performed using TopHat v2.1.0 to the mm10 genome. BAM files were merged on a per sample. Exon and gene level counting were performed using the easyRNASeq version 2.4.7 package. A binary annotation file, built using the annotation file generation function of EasyRNASeq, was used for this analysis; the Ensembl release 83 GTF file was used as input. Annotation was performed using a Gene Transfer Format (GTF) annotation file for Mus musculus, which was downloaded on February 11, 2016 and contains the current Ensembl Mouse release 83. Filtering of the RPKM values was performed to retain a list of genes with a minimum of approximately 50 mapped reads in 25% or more samples. The threshold of 50 mapped reads is considered the Reliable Quantification Threshold, as the RPKM values for a gene represented by 50 reads should be reproducible in technical replicates. To avoid reporting large fold changes due to random variation of counts from low abundance mRNA, RPKM values equivalent to a count of ≤10 reads per gene were replaced with the average RPKM value equivalent to 10 reads/gene across all the samples in the experiment.

An unpaired two-sample heteroscedastic *t*-test was performed on the log~2~ RPKM values to compare the overall effects of age (PND2 or 4 month) on gene expression. Fold changes were also calculated for 4 month / PND2 using the mean of each group being compared. If the mean of both groups considered in the fold change comparison was below RQT, "NA" is reported. All statistical analysis was performed using R version 3.2.2 statistical computing software. A total of 7,496 genes were determined to have a low FDR-value (FDR \<0.1) for the unpaired *t*-test. Full dataset is available through NCBI GeoDatasets, accession code GSE108083, "RNA-seq analysis of aortic heart valves in mice".

RNA-Sequencing Data Analysis {#s2-6}
----------------------------

A heatmap was generated from 23,303 differentially expressed genes. Log2 transformed RPKM values were utilized and hierarchical clustering analysis was performed with Cluster 3.0 software ([@B21]). Genes and samples were clustered using centered correlation as the similarity measure and average linkage as the clustering method. A volcano plot was generated utilizing ggplot2 and is plotted as the -Log10(*p*-value) vs. Log2 Fold Change. The volcano plot highlights the differential gene expression between postnatal day 2 and 4 month aortic valves. A Venn diagram was generated based only on genes with a low *t*-test *p* value (*p* \< 0.05), a fold change \>2, and RPKM values above the Reliable Quantification Threshold for all biological replicate samples from either group. If at least one of the gene reads from a triplicate set was proven undetectable while all gene reads in the comparative sample set was proven detectable, the gene was considered to be uniquely expressed. If the gene read from both triplicate sample sets had detectable RPKM values about the Detection Threshold, the gene was considered common amongst sample groups. Genes with at least one triplicate below the Detection Threshold in both samples sets are not represented in the Venn diagram.

Functional annotation was performed through the utilization of Database for Annotation, Visualization, and Integrated Discovery (DAVID) version 6.8 ([@B22]). 2,082 differentially expressed genes with an FDR \<0.05 and fold change \>2, were assessed utilizing Gene Ontology (GO) FAT terms, which were employed to filter out broad GO categories based on a measured specificity of each term. Visualization of GO term analysis was performed using the GOPlot R package version 1.0.2 ([@B23]). To reduce the redundancy of GO terms, the reduce overlap function was used, with the threshold set to 0.75, which removes GO terms that have a gene overlap greater than or equal to the set threshold. Bubble plots were generated for the reduced GO term list using the GoBubble function, and the top 15 GO terms from biological processes, cellular component, and molecular function were visualized. Each bubble represents a term, where the size of the bubble correlates to the number of genes within the term, and it is plotted as --log (FDR) vs. z-score. The z-score is a crude measurement, predicting if a term will be upregulated or downregulated, and is calculated by taking the number of upregulated genes and subtracting the number of downregulated genes and then dividing this number by the square root of the number of genes in each pathway. The circle plot was generated using the GoCircle function, and highlights the gene expression changes within each of the selected terms. The circle plot highlights the overall gene expression change by showing increased expression in red and decreased expression in blue. The circle plot also highlights the *p*-value of the GO term by the height of the inner rectangle, which is also colored by z-score. A chord plot was generated using the GoChord function, and it represents 59 differentially expressed genes and their correlation to the following associated terms: extracellular matrix, cell proliferation, cell cycle, mitotic cell cycle process, defense response, and regulation of immune system processes. The chord plot also highlights the log fold change of each differentially expressed gene that is shown.

qRT-PCR {#s2-7}
-------

RNA was extracted from isolated aortic valves from PND2 and 4 month old *C57BL/6J* mice to validate RNA-seq findings. Briefly, Trizol reagent (Invitrogen) was used to extract RNA according to manufacturer's instructions, and cDNA and PCR reactions were performed as previously described by our lab ([@B24]). Primers for genes selected for validation were designed in NCBI Primer-BLAST based on FASTA sequence and shown below:

  **Gene name**    **Forward primer sequence (5^**′**^ to 3^**′**^)**   **Reverse primer sequence (5^**′**^ to 3^**′**^)**
  ---------------- ---------------------------------------------------- ----------------------------------------------------
  ***Nid2***       AGGAGTGAGCATGTTTCGG                                  AGGGGTATTGCCAGCTTCAC
  ***Mmp3***       TGCATGACAGTGCAAGGGAT                                 ACACCACACCTGGGCTTATG
  ***Marckls1***   CCCGTGAACGGAACAGATGA                                 CCCACCCTCCTTCCGATTTC
  ***Gsn***        GGGACGGCCGGTTACTTAAA                                 CTTCAGGAATTCGGGGTGCT
  ***Filip1l***    AGGCTCCACTGCTGGATTTC                                 GACTTCTCTGACACGGGACG
  ***Myoc***       ACGACACTAAAACGGGGACC                                 TTCTGGCCTTTGCTGGTAGG
  ***Retnla***     GGAACTTCTTGCCAATCCAGC                                CAGTGGTCCAGTCAACGAGT
  ***Npdc***       GCACTCCCGACACTTTTCTC                                 GGTACCCACTCCGGGAACT
  ***Sfrp4***      CCTGGCAACATACCTGAGCA                                 AGCATCATCCTTGAACGCCA
  ***Mki67***      AGAGCTAACTTGCGCTGACT                                 ACTCCTTCCAAACAGGCAGG
  ***Nrg1***       CCATCTCTCGATGGGCTTCC                                 ATGCAGAGGCAGAGGCTTAC
  ***Nrep***       GCATGATGCCCTTTTTCATCCA                               TCCTTAGGCACGGGAAGTCT
  ***Acta2***      CCTTCGTGACTACTGCCGAG                                 GAAGGTAGACAGCGAAGCCA
  ***Dlk1***       AGAGTACCCCTCTCCTCACC                                 CGCCGCTGTTATACTGCAAC
  ***Cfd***        TACATGGCTTCCGTGCAAGT                                 GGGTGAGGCACTACACTCTG

Quantitative real-time PCR using a Step One Plus Real Time PCR system (Applied Biosystems) was used to detect changes in gene expression with Sybr Green reagents. Cycle counts for each target gene were normalized to *β-actin* expression and differences in gene expression were reported as a fold change from the 4 month time point. Statistical analysis was performed in GraphPad Prism 7.0a.

Results {#s3}
=======

Postnatal Valve Maturation and Adult Maintenance Are Associated with Distinct Transcriptional Profiles {#s3-1}
------------------------------------------------------------------------------------------------------

As previously described, the valve structures continue to grow and remodel after birth ([@B1]). As shown by Movat's Pentachrome stain, murine aortic valve structures at postnatal day 2 (PND2) are thick and composed of predominantly proteoglycan (blue), with less extensive collagen and elastin ([Figure 1A](#F1){ref-type="fig"}). By 4 months of age, the leaflets have elongated and display distinct layers of collagen (fibrosa, yellow), proteoglycan (blue), and elastin (black) ([Figure 1B](#F1){ref-type="fig"}).

![Postnatal and adult aortic vales display differences in ECM composition and gene expression. Movat's Pentachrome staining to show extracellular matrix composition at PND2 **(A)** and 4 months **(B)** (black: elastic fibers and cell nuclei, blue: proteoglycans, yellow: collagen, red: muscle and fibrinoids). **(C)** Venn diagram to show distribution of the detected mRNAs that were uniquely or commonly expressed at PND2 or 4 months. **(D)** RT-qPCR validation (black bars) of RNA-seq findings (white bars) (*n* = 3, \*:*p* \< 0.05; two-tailed unpaired *t*-test, \#:FDR \<0.05). Ao, aorta; AoV, aortic valve.](fcvm-05-00030-g001){#F1}

In order to further define molecular profiles associated with the structural changes in postnatal and 4 month old aortic valves, we performed RNA-sequencing on isolated samples. Overall, RNA expression for samples consistently clustered by time point, as shown several ways including a Pearson's correlation matrix (data not shown), principal component analysis (PCA) (data not shown) and hierarchical heatmap ([Figure 2A](#F2){ref-type="fig"}). Of 23,303 detectable genes, 3,659 genes were found to have a *p*-value \< 0.05 and a fold change \>2, and include 1,858 upregulated and 1,801 downregulated transcripts. Of these 3,659 differentially expressed genes, 602 were unique to the PND2 time point and include *Dlk1*, *Hif3a, Agtr2* and *S100A9*, while 477 were only expressed at 4 months (*Cfd, Rtn1a, Clec3a, Adipoq, etc.*), leaving 2,580 common to both groups ([Figure 1C](#F1){ref-type="fig"}). [Table 1](#T1){ref-type="table"} includes the top 20 mRNAs uniquely expressed at each time point based on RPKM value, which is indicative of mRNA abundance. Additional RT-qPCR analysis of independent cDNA samples validated RNA-seq findings in 10 out of 12 genes (85%) at a significance threshold of *p* \< 0.05 ([Figures 1D, 4A and 5A,D](#F1 F3 F4 F5){ref-type="fig"} and data not shown).

![RNA-seq analysis reveals transcriptional differences between PND2 and 4 month old murine aortic valves. **(A)** Hierarchical heatmap cluster shows clustering analysis of biological replicates (*n* = 3). **(B)** Volcano plot of differentially expressed genes sorted according to fold change and significance (FDR). Green dots represent genes with log2 fold change \>1 and FDR \<0.05, pink dots represent genes with FDR \< 0.05, and blue dots represent genes with log2 fold change \>1.](fcvm-05-00030-g002){#F2}

###### 

Top 20 unique genes at PND2 and 4 month time points.

  **PND2**        **4** Month
  --------------- ---------------
  Dlk1            Cfd
  Hif3a           2210407C18Rik
  Agtr2           Retnla
  S100a9          Clec3a
  Slc38a5         Adipoq
  Col24a1         Ces1d
  Bmp7            Thrsp
  Vash2           Pck1
  Igf2bp3         Mgl2
  Stfa1           C7
  S100a8          Inmt
  Cited1          Cidec
  Gm5483          Fmo3
  Frem2           Angpt4
  Gipr            Hamp
  Ube2c           Art1
  Dctd            Tmem45b
  1110032F04Rik   Olfr224
  C1qtnf3         Plin1
  Cdkn3           Rpl3l

Genes are listed in order of RPKM with the most highly expressed at the top of the list. Only genes with a low t-test p value (t-test P: Age \< 0.05), a Fold Change: 4mo/P2 \>2 up/down, and above the Reliable Quantification Threshold in all samples from either group (i.e., the gene RPKM values were \>RQT in all three P2 samples or in all three 4mo samples) were retained for further filtering.

Transcriptional Analysis Identifies Age-Dependent Transcriptional Profiles and Biological Functions {#s3-2}
---------------------------------------------------------------------------------------------------

Heatmap hierarchical clustering analysis, where 23,300 differentially expressed genes and samples were clustered using center correlation as the similarity measurement and average linkage as the clustering method, revealed molecular similarities between biological replicates at each time point and distinct differences between PND2 and 4 months ([Figure 2A](#F2){ref-type="fig"}). Additional volcano plot analysis graphically displays the differential expression of 23,300 individual transcripts based on significance and fold change ([Figure 2B](#F2){ref-type="fig"}). To determine functions associated with differential gene expression changes at each time point, Gene Ontology (GO) pathway analysis was performed. The bubble plot in [Figure 3A ](#F3){ref-type="fig"}visualizes the biological processes, cellular components, and molecular functions enriched by the differential data set and the table highlights the top 15 GO terms represented. These include biological processes such as cell proliferation, mitotic cell cycle, and defense response, along with cellular components such as extracellular matrix (ECM), indicating that valve maturation involves considerable changes in cell proliferation, ECM composition, and immune system programs. This is further highlighted in [Figure 3B ](#F3){ref-type="fig"}circle plot displaying genes which are known to be expressed in the heart valves based on previous publications, and their association with each GO term. More specific trends in these GO terms are shown in [Figure 3C](#F3){ref-type="fig"}, with individually upregulated and downregulated genes in each category shown as red and blue dots, respectively. The inner rectangles are sized to positively correlate with the significance of each GO term, and colored to represent the overall direction of change in expression of each individual term. For example, the term "mitotic cell cycle process" has an overall down regulation at 4 months of age, while the "defense response" has an overall upregulation. In contrast, the "extracellular matrix" GO term is overall neither up-, nor downregulated, but the change in many individual transcripts is significant. Together these genomic analyses have defined transcriptional profiles of PND2 and 4 month aortic valve structures, and identified changes in functions associated with these mRNA patterns.

![Pathway analysis identifies diverse key biological processes, cellular components and molecular functions between PND2 and 4 month old murine aortic valves. **(A)** Gene ontology (GO) analysis reveals top differentially regulated GO terms, graphically displayed according to significance (*p*-value) and z-score, a measure of overall up or down regulation for the category. Data represented as a bubble plot (left). The size of each circle represents the number of differentially expressed genes in that GO term, while color represents the category (green: biological process pink: cellular component, blue: molecular function). Table (right) lists the top GO terms along with count, FDR, and z-score. **(B)** Chord plot showing 59 differentially expressed genes previously associated with healthy and diseased valves, and their overlap between significant GO terms as determined in **(A)**. Color below each gene corresponds to log fold change, with red representing increased expression at the 4 month time point and blue representing decreased expression at 4 months. **(C)** Circular plot highlighting gene expression differences within each selected GO term, with each red dot depicting a gene upregulated at 4 months in that category, and each blue dot showing a gene downregulated at 4 months. The height of the inner rectangle represents the *p*-value of the GO term and is colored according to z-score, with red being increased at the 4 month time point and blue being decreased at 4 months.](fcvm-05-00030-g003){#F3}

Proliferation Programs Are Downregulated in 4 month Old Aortic Valves {#s3-3}
---------------------------------------------------------------------

Based on enrichment of cell proliferation-related genes from GO analysis ([Table 2](#T2){ref-type="table"}), we first validated the fold change trends observed by RNA-seq using RT-qPCR ([Figure 4A](#F4){ref-type="fig"}) on independent biological samples. These validated genes include three positive regulators of proliferation *mKi67, Nrg1* and *Marcksl1*, which all decreased in 4 month old aortic valves, and an anti-proliferative gene, *Sfrp4*, found to have increased expression at this time point ([Figure 4A](#F4){ref-type="fig"}) ([@B25]--[@B28]). To further validate mRNA findings, we utilized 5-ethynyl-2′-deoxyuridine (EdU) to visualize and compare the number of cells actively undergoing mitosis in the aortic valve at PND2 and 4 months of age ([Figure 4B](#F4){ref-type="fig"}-D). At the earlier time point, \~10.5% of cells were found to be EdU-positive, while only 0.16% of cells were proliferating at 4 months ([Figure 4B](#F4){ref-type="fig"}). These data are consistent with transcriptional changes and previous reports from our lab showing that \~6.2% of VECs (of the total VEC population) and \~3.3% of VICs (of the total VIC population) are proliferative at post natal stages, while in the young adult, proliferation rates of both VECs (\~2%) and VICs (\~1.1%) were significantly lower ([@B4]). Together, these observations suggest that a decline in cell division at 4 months is due to a combination of decreasing expression of postnatal proliferation programs while simultaneously increasing adult programs which inhibit proliferation.

###### 

Genes included in the "Cell Proliferation" GO term.

  **Downregulated at 4 months**   **Upregulated at 4 months**
  ------------------------------- -----------------------------
  AGTR2                           ADIPOQ
  H19                             HSPA1A
  BMP7                            CD74
  VASH2                           PLA2G2D
  IGF2                            RBP4
  IGF2BP1                         H2-AA
  FAM83D                          H2-AB1
  CTHRC1                          VSIG4
  CRH                             CCL19
  CDK1                            CRLF1
  NRK                             CCL11
  BEX1                            NOX4
  BUB1                            SFRP4
  IL31RA                          CD209A
  MELK                            PTGFR
  SCUBE2                          BCL6
  CCNB1                           ITGAX
  FIGNL1                          KCNA1
  AURKB                           LGI4
  UHRF1                           ATF3
  AGER                            PTGS2
  CDCA7L                          AR
  SHCBP1                          ESR1
  WISP1                           CFB
  NRG1                            CEBPA
  MKI67                           APOD
  HELLS                           MMP12
  ASPM                            IL2RA
  MCM10                           RUNX3
  IQGAP3                          NR4A1
  KIF20B                          HSF4
  MARCKSL1                        CD274
  BIRC5                           ALDH3A1
  RACGAP1                         IFIT3
  ROR2                            FGF7
  CHEK1                           IL7R
  TNC                             CLEC11A
  CDH3                            WFDC1
  SFRP2                           AGAP2
  E2F8                            FLT3L
  E2F7                            FOLR2
  SOX4                            LIMS2
  CDC20                           GAPT
  CENPF                           SERPINF1
  PTN                             NR1D1
  WNT4                            FGF16
  IRF6                            BMPR1B
  F2RL1                           SERPINE2
  FOXM1                           IGHD
  HMGA2                           F3
  MYCN                            WNT10B
  CD40                            TRPV2
  CDC6                            CD28
  MMP14                           MLXIPL
  TACC3                           SIX1
  EDN1                            CPEB1
  HMGB2                           CYR61
  SMARCA1                         PTGIR
  LAMC2                           ECM1
  GPC3                            THPO
  PROX1                           CX3CL1
  VASH1                           ITGB2
  CD276                           ABCB1A
  RNASEH2B                        THRB
  NASP                            H2-M3
  BLM                             TOB2
  ORC1                            CHD5
  NKX2-5                          MUSTN1
  CDK2                            SAMD9L
  TFRC                            FTH1
  LOXL2                           PODN
  CXADR                           PTPRC
  CASP3                           FCGR2B
  SLIT2                           S100B
  CAV3                            FOSL2
  DBN1                            ATF5
  EFNB2                           COL18A1
  FN1                             BTG2
  CDH5                            PTPRU
  SMYD2                           COL4A3
  TNFRSF13C                       IL15
  CDKN1C                          NOV
  DOT1L                           FBLN1
  RPS6KA2                         JUN
  SNAI2                           PTAFR
  MEG3                            ADRB2
  RIAN                            SPN
  RRM1                            HAVCR2
  HAS2                            IL33
  GM13275                         RORA
  DDR1                            LRP1
  ATPIF1                          NTN1
  GATA6                           ITGAM
  ERBB2                           LEFTY1
  MCM7                            PID1
  DISC1                           GAS6
  SCARB1                          CST3
  CTPS                            EGR3
  PTPRK                           NAMPT
  PTPRF                           PDGFD
  EDNRA                           CD37
  CD24A                           CD9
  SLC25A5                         SLC11A1
  TEK                             CNN1
  TRIM35                          MVP
  CNOT6                           ANGPT1
  KDM5B                           H2-T23
  PICALM                          DOCK8
                                  TSPO
                                  CD86
                                  NACC2
                                  SPHK2
                                  HCLS1
                                  IRS2
                                  ZFP36
                                  CDKN1A
                                  TRF
                                  SLFN1
                                  IGFBP4
                                  RHBDD1
                                  DPT
                                  TNS2
                                  DOCK2
                                  NCF1
                                  PIK3CB
                                  APOE
                                  PAWR
                                  CD46
                                  CSF1
                                  IRF1
                                  CNTFR
                                  TACC2
                                  TGFBR3
                                  NUPR1
                                  BCL2
                                  VIPR2
                                  PTTG1
                                  TLR4
                                  RUNX2
                                  HYAL1
                                  IGFBP5
                                  CSF1R
                                  NCOA3
                                  PAK1
                                  PDE5A
                                  BRIP1
                                  CORO1A
                                  IFITM3

Genes are sorted according to fold change with the highest fold change at the top of the list.

![Positive regulators of cell proliferation are enriched at PND2 in murine aortic heart valves. **(A)** RT-qPCR performed on independent samples (black bars) validates the RNA-seq fold change (white bars) trends for proliferation-related genes. Expression is normalized to 1, indicated by the x-axis. (n=3, \*:*p*\<0.05; two-tailed unpaired *t*-test, \#:FDR\<0.05). **(B)** Quantification of 5-ethynyl-2′-deoxyuridine (EdU) positive cells as a percentage of total cell nuclei (indicated by DAPI, blue) at PND2 and 4 month time points. (n=3, \*:*p*\<0.05, two-tailed unpaired *t*-test). **(C)** Representative images of staining for incorporation of EdU into replicating DNA (white arrows point to EdU-positive cells) reveals high levels of proliferation in PND2 AoV as compared to **(D)** EdU staining in 4 month old aortic valve. Ao, aorta; AoV, aortic valve; Myo, myocardium.](fcvm-05-00030-g004){#F4}

Postnatal and Adult Aortic Valves Have Distinct Extracellular Matrix mRNA Programs {#s3-4}
----------------------------------------------------------------------------------

As indicated by the GO term z-score in [Figure 3A](#F3){ref-type="fig"}, the overall expression of ECM transcripts does not significantly increase or decrease with age, yet there are considerable differences in the specific ECM-related mRNAs that are expressed between the two time points ([Table 3](#T3){ref-type="table"}). Matrix metalloproteinases, or Mmps, are known to be expressed in both healthy and diseased valves and are associated with physiological and pathological remodeling of the ECM respectively ([@B29]--[@B31]). Also known as stromelysin-1, Mmp3 targets degradation of proteoglycans, collagens, and elastins ([@B32]) and this Mmp family member has been described in cancer ([@B33],[@B34]), but little is known about Mmp3 in mouse valves. In this study, *Mmp3* increased from 1.22 reads per million kilobases (RPKM) at PND2 to 86.14 RPKM at 4 months. This significant increase was confirmed by RT-qPCR ([Figure 5A,B](#F5){ref-type="fig"}) and immunofluorescence of aortic valve tissue sections, where Mmp3 is localized primarily to the sub-endothelial region of the leaflet ([Figure 5B](#F5){ref-type="fig"}, [Figure S1](#SF1){ref-type="supplementary-material"}). In our previous VEC RNA-seq study, *Mmp3* transcript was not detected in the VEC population at any time point ([@B4]), and this is consistent with predominant expression of the protein in VICs; largely those close to the sub-endothelial location at 4 months (arrows, [Figure 5C](#F5){ref-type="fig"}, [Figure S1](#SF1){ref-type="supplementary-material"}). In this study we show that the basement membrane ECM protein *Nidogen 2* (*Nid2*) was more highly detected in PND2 samples at 76 RPKM, while only 15 RPKM were detected at 4 months. This expression pattern was confirmed by RT-qPCR ([Figure 5D](#F5){ref-type="fig"}) and immunofluorescence data shows broad Nid2 localization in both VECs and VICs at PND2, but more localized within the endothelial cell layer at 4 months ([Figure 5E,F](#F5){ref-type="fig"}, [Figure S1](#SF1){ref-type="supplementary-material"}), and this pattern of decreased expression with maturation is consistent at the RNA level in VECs as previously described ([@B4]). These data show that PND2 and 4 month old aortic valves have distinct ECM-related transcriptional profiles associated with growth and maintenance respectively.

![ECM molecular profiles between PND2 and 4 month old murine aortic valves are distinct.**(A)** RT-qPCR performed on independent samples (black bars) validates the trends seen in RNA-seq data (white bars). Expression is normalized to 1, indicated by the x-axis (n=3, \*:*p*\<0.05; two-tailed unpaired *t*-test, \#:FDR\<0.05). **(B)** Immunofluorescence staining for Mmp3 reveals low expression at PND2 compared to **(C)** 4 months (white arrows indicate Mmp3-positive cells). **(D)** RT-qPCR performed on independent samples (black bars) validates the trends seen in RNA-seq data (white bars) for ECM gene *Nid2*. Expression is normalized to 1, indicated by the x-axis (n=3, \*:*p*\<0.05; two-tailed unpaired *t*-test, \#:FDR\<0.05). **(E)** Immunofluorescence staining for Nid2 reveals high expression atPND2 (white arrows indicate Nid2-positive cells) compared to **(F)** Nid2 staining at the 4 month timepoint. Ao, aorta; AoV, aortic valve.](fcvm-05-00030-g005){#F5}

###### 

Genes included in the "Extracellular Matrix" GO term.

  **Downregulated at 4 months**   **Upregulated at 4 months**
  ------------------------------- -----------------------------
  S100A9                          MYOC
  COL24A1                         MMP3
  BMP7                            GLDN
  2010005H15RIK                   CHAD
  CTHRC1                          MMP10
  FREM2                           COMP
  COL26A1                         ENTPD2
  ELN                             LAMC3
  COL9A1                          CILP2
  FREM1                           SOD3
  ADAMTS12                        FBLN7
  FRAS1                           NPNT
  MFAP2                           PRELP
  ADAMTS17                        MMP12
  WISP1                           COL4A6
  HMCN1                           VIT
  LAMA1                           CCBE1
  COL12A1                         CPXM2
  ACAN                            OPTC
  TNC                             SERPINF1
  FREM3                           SERPINE2
  LAMB1                           F3
  LOX                             CRISPLD2
  EMILIN3                         WNT10B
  TFPI2                           EPYC
  NID2                            AEBP1
  PTN                             CYR61
  WNT4                            ECM1
  MMP15                           ECM2
  FBLN2                           PODN
  MMP14                           SMOC2
  TPSB2                           COL5A3
  PXDN                            TIMP3
  LAMC2                           SMOC1
  GPC3                            COL18A1
  ADAMTS9                         DCN
  GPC2                            HIST1H4C
  NID1                            COL4A3
  LOXL2                           NOV
  ANGPTL4                         FBLN1
  SLIT2                           SPARCL1
  WNT5B                           SPN
  VCAN                            NTN1
  CMA1                            RARRES2
  FN1                             CST3
  COL5A1                          LGALS3BP
  COL5A2                          IGFBP7
  LAMA3                           VWA1
  P3H1                            MGP
  TUBB5                           TNXB
  AGRN                            COL15A1
  SFPQ                            BGN
  ITGA6                           THSD4
  LAMC1                           HIST1H4A
  SLC25A5                         TRF
  CD93                            LAMB2
  COL4A1                          DPT
                                  LMCD1
                                  APOE
                                  ADAMTSL5
                                  TGFBR3

Genes are sorted according to fold change with the highest fold change at the top of the list.

Gene Ontology Defense Response Markers Are Highly Enriched in 4 month Old Aortic Valves {#s3-5}
---------------------------------------------------------------------------------------

As shown in [Figure 6A](#F6){ref-type="fig"} and [Table 4](#T4){ref-type="table"}, a large majority (77%) of defense response genes are most highly expressed in aortic valve structures at 4 months of age and include *Ccl19, Ptgs2* and *Cxcl9*. The increased expression of *Ptgs2* (also known as *Cox2*) ([Figure 6B,C](#F6){ref-type="fig"}) and *Rarres2* (also known as *﻿Tig2*) ([Figure 6D,E](#F6){ref-type="fig"}) are confirmed here by immunofluorescence. Ptgs2 is an enzyme involved in the synthesis of prostaglandins which are known to mediate pain and inflammation responses ([@B35]), and has been described in the valve as a pro-osteogenic marker ([@B36]). Consistent with this previous valve study, we observed expression towards the endothelium at 4 months of age ([Figure 6C](#F6){ref-type="fig"}, [Figure S1](#SF1){ref-type="supplementary-material"}), and this is consistent with RNA expression in the VEC population ([@B4]). Like Ptgs2, Rarres2 is also known to regulate inflammation and has been linked with hypertension ([@B37]), a known risk factor of aortic valve stenosis ([@B38]). By immunofluorescence, Rarres2 is widely expressed throughout the valve leaflet including VECs and VICs at 4 months of age, which is a significant increase compared to PND2 ([@B4]). Overall, our RNA-seq data shows that expression of defense response-related genes increases with age in the murine aortic valve.

![Expression of defense-related genes increases with valve maturation. **(A)** RNA-sequencing fold changes of defense-related genes. Expression is normalized to 1, indicated by the x-axis (\#:FDR \< 0.05). **(B)** Immunofluorescence staining for Ptgs2 validates RNA-seq trends, showing low expression at PND2 compared to **(C)** Ptgs2 staining at the 4 month time point (white arrows indicate Ptgs2-positive cells). **(D)** Immunofluorescence staining for Rarres2 validates RNA-seq trends, showing low expression at PND2 compared to **(E)** Rarres2 staining at the 4 month time point. Ao, aorta; AoV, aortic valve.](fcvm-05-00030-g006){#F6}

###### 

Genes included in the "Defense Response" GO term.

  **Downregulated at 4 months**   **Upregulated at 4 months**
  ------------------------------- -----------------------------
  AGTR2                           CFD
  S100A9                          ADIPOQ
  CITED1                          HAMP
  IGF2                            HP
  COLEC10                         CD74
  NGP                             CCL8
  C1QTNF3                         H2-AA
  CRH                             H2-EB1
  S100A8                          H2-AB1
  IL31RA                          CLEC10A
  ADAMTS12                        GM2564
  CHAF1B                          CCL19
  AGER                            CCL11
  PBK                             C4B
  ULBP1                           C4A
  RNASEL                          PTGFR
  RAET1E                          BCL6
  ELF3                            ITGAX
  BRINP1                          PTGS2
  RAET1D                          ESR1
  F2RL1                           CFB
  CD40                            APOD
  LCK                             IL2RA
  MASP1                           H2-Q7
  TPSB2                           FFAR4
  MDK                             CXCL9
  EDN1                            ITIH4
  HMGB2                           SLAMF7
  SLFN9                           C1S1
  CPA3                            IFIT3
  CD276                           C1S2
  TSPAN6                          GBP2
  TYRO3                           FGF7
  CASP6                           C1RA
  CCR1                            C1RB
  SLIT2                           WFDC1
  FN1                             OAS2
  GM13275                         GPR17
  GGT5                            PELI3
  HYAL2                           MYLK
  EDNRA                           CFH
  CD24A                           ISG20
  FANCA                           H2-K1
  TRIM35                          SERPINF1
  SUSD4                           NR1D1
  CD93                            CLEC7A
  SLC35B3                         BMPR1B
                                  C1RL
                                  F3
                                  LYZ1
                                  TGTP1
                                  SLAMF8
                                  TGTP2
                                  ITK
                                  HRH1
                                  ALOX5
                                  CD28
                                  NR1H3
                                  PSTPIP1
                                  IRAK3
                                  LYZ2
                                  H2-D1
                                  TAP2
                                  APOBEC1
                                  GNG7
                                  PTGIR
                                  ECM1
                                  CX3CL1
                                  ITGB2
                                  CD14
                                  CCRL2
                                  HIST2H3C2
                                  GBP6
                                  GBP10
                                  H2-M3
                                  C3
                                  MILL2
                                  SERPING1
                                  CYBB
                                  PTPRC
                                  FCGR2B
                                  RAB7B
                                  HIST1H2BE
                                  TRIM30A
                                  NFKBIZ
                                  ICAM1
                                  SLFN8
                                  IFIH1
                                  HIST1H2BJ
                                  FAS
                                  IL15
                                  NOV
                                  PTAFR
                                  MAP1A
                                  CASP1
                                  MYO1F
                                  ADRB2
                                  FGF14
                                  HIST1H2BC
                                  SPN
                                  HAVCR2
                                  IL33
                                  B2M
                                  COLEC12
                                  RORA
                                  ITGAM
                                  TAP1
                                  RARRES2
                                  CST3
                                  ZC3H12A
                                  IRGM2
                                  NAIP5
                                  HIST1H2BL
                                  IGTP
                                  PNMA1
                                  HIST1H2BK
                                  CD37
                                  TLR8
                                  SLC11A1
                                  MGLL
                                  IL17RE
                                  HIST1H2BN
                                  CADM1
                                  H2-T23
                                  HERC6
                                  CD86
                                  SETD6
                                  ZFP36
                                  THEMIS2
                                  LDLR
                                  HFE
                                  C1QA
                                  IGFBP4
                                  LMCD1
                                  ALOX5AP
                                  NCF1
                                  GBP8
                                  APOE
                                  TNFRSF25
                                  SERPINB9
                                  CD46
                                  CSF1
                                  IRF1
                                  NUPR1
                                  BCL2
                                  STAR
                                  DRD1
                                  PIK3AP1
                                  IRF8
                                  TLR4
                                  TLR3
                                  BIRC3
                                  HYAL1
                                  CSF1R
                                  C1QB
                                  UNC93B1
                                  TRIM21
                                  PDE5A
                                  PTGIS
                                  CORO1A
                                  AOAH
                                  IFITM3

Genes are sorted according to fold change with the highest fold change at the top of the list.

Discussion {#s4}
==========

This current study explores transcriptional differences in PND2 and 4 month old murine aortic valve expression profiles with the goal of identifying genetic programs representative of valve growth and valve maintenance, respectively. Long term, this may be important for the development of alternative therapies; specifically, those exploring the growth or regenerative capacity of adult diseased valves. Our results indicate that at PND2, dynamic leaflet growth is associated with a unique transcriptional profile compared to homeostatic adult valves at 4 months. Of the 23,303 detectable genes in our RNA-seq data, the number of differentially expressed transcripts found to be up and down regulated at each time point were approximately equal, suggesting that gene transcription patterns were not overtly altered, but rather transitioned from a postnatal to adult expression profile. Such profiles are related to enriched biological functions including cell proliferation at PND2 and defense response at 4 months of age. Interestingly, ECM components were enriched at both time points, but the associated mRNA profiles were unique. Together these analyses contribute to the current knowledge and further advance our understanding of the molecular signatures and biological functions characteristic of the whole aortic valve structure at PND2 and 4 months. provide critical information related to genetic programs in the growing and homeostatic heart valve.

PND2 murine aortic valves are defined by a specific transcriptional profile including the unique expression of 602 genes ([Figure 1C](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}) that were not detected at 4 months of age. In addition, 1,801 transcripts were upregulated at PND2, while 1,858 were decreased compared to the adult homeostatic valve. According to Gene Ontology analysis, many of the transcripts enriched at PND2 suggest an overall upregulation of active cell proliferation by a specific set of genes. These include increased expression of those associated with active cell division (*Ki67, Aurkb*), pro-proliferation markers (*Bub1, Cdk1, Foxm1, Nrg1*) ([@B27],[@B40]) and decreased expression of proliferation inhibitors (*Nox4, Sfrp*) ([@B41]--[@B44]). This specific expression profile of cell proliferation markers supports EdU observations and represents active elongation of the immature valve structure. It will become important to understand how this molecular signature of cell proliferation is downregulated after maturation is complete and explore the potential of re-introducing key regulators to stimulate cell division and replenish dysfunctional cell populations in the adult following injury or disease.

In addition to high levels of cell proliferation, the PND2 valve is characterized by a specific ECM mRNA profile ([Table 3](#T3){ref-type="table"}) which likely corresponds to the mechanical demands during the postnatal period. When comparing PND2 to 4 months, RNA-seq analysis reveals significant enrichment of highly expressed fibrillar collagens including *Col24a1*, *Col9a1*, and *Col5a1*, indicating the need for additional stability as the growing postnatal valve adapts to hemodynamic changes in response to closing of the foramen ovale ([@B45],[@B46]). RNA-seq analysis also uncovered higher PND2 levels of ECM proteins such as *Frem1/Frem2* and *Nidogen2* (*Nid2*), which have been shown to stabilize basement membranes underlying endothelial cells and may provide further structural integrity to the developing valve ([@B47],[@B48]). Besides identifying the enrichment of differentially expressed fibrillary collagens and specific proteoglycans, RNA-seq analysis shows that the PND2 valve also expresses a distinct profile of ECM enzymes, such as *Mmp15* and *Adamts17*, indicating the need for physiological remodeling during growth and maturation

The 4 month adult valve is physically and molecularly distinct from the postnatal valve, with elongated leaflets containing distinct layers of collagen, proteoglycan, and elastin ([Figure 1B](#F1){ref-type="fig"}). At this time point, 477 transcripts were found to be uniquely expressed, with the most abundant unique mRNAs including *Cfd*, *Retnla*, and *Clec3a*. In contrast to the PND2 aortic valve, the adult valve displays significantly decreased levels of cell proliferation, likely due to increased expression of proliferation inhibitors and lack of enrichment of positive regulators. At 4 months, the valve ECM is diverse compared to PND2 ([Table 3](#T3){ref-type="table"}) and likely reflects differences in biomechanical demand in response to the adult circulatory system ([@B49],[@B50]). Similar to the PND2 valve, collagens and proteoglycans are predominant. However, the most highly differentially expressed collagens are those associated with basement membranes, including *Col4a6* and *Col18a1*, which act as a cell scaffold to maintain current cell populations and cell integrity as opposed to providing support for high cell turnover. In addition, the proteoglycan profile is moved towards enrichment of decorin (*DCN*) and biglycan (*BGN*) consistent with previous studies in aging pigs ([@B51]). Furthermore, the contribution of ECM remodeling enzymes is shifted to *Mmp3* and its inhibitor *Timp3* at 4 months, possibly indicating a differential need of the ECM to sustain homeostasis. Previous studies have suggested correlations between VIC phenotype and ECM composition ([@B52],[@B53]) and therefore we anticipate that our findings at 4 months are related to the quiescent VICs, while the diversity at PND2 is dictated by proliferative and active VICs.

One of the most prominent differences in expression profiles between the PND2 and 4 month aortic valve is the considerable upregulation of defense-related transcripts at the older time point, indicating increased immune system activation with valve maturation ([Figure 6](#F6){ref-type="fig"}, [Table 4](#T4){ref-type="table"}). Previous studies from other groups have shown that the appearance of immune markers such as *Ptgs2* and *Rarres2* precedes the onset of disease both in the heart valve and other cardiovascular systems ([@B36],[@B37]). In addition, there is increasing evidence to suggest that inflammation in the valve is an initial homeostatic repair mechanism activated in response to minor valve injuries sustained throughout life, but that this repair mechanism may become pathogenic if overactive or long-lasting \[reviewed ([@B54])\]. Our study suggests that some level of activation of the immune system in the valve is present at 4 months of age under homeostatic conditions, however, it is not clear whether these defense markers are an early indication of valve degeneration, or a root cause of disease themselves. Further investigation into target genes such as *Cfd* and *Adipoq* will give insight into the possible role of defense response genes in valve disease therapeutics.

Our data shows that postnatal heart valves contain highly proliferative VICs producing a distinctive set of postnatal ECM proteins, while adult VICs are mainly quiescent and are associated with a very different ECM composition as well as increased defense response markers. A limitation of our study is that RNA-seq analysis was performed on whole valve tissue and therefore RNA profiles cannot be distinguished between VEC and VIC populations, however IHC studies shown here, in combination with a previous study from our group ([@B4]) support enrichment towards one cell type. Nonetheless, we have unveiled multiple conceivable processes that contribute to postnatal valve maturation and maintainence that pave the way for elucidiating mechanisms underlying valve defects present at birth and those acquired later in life. Furthermore, the basic priciples of cell proliferation and ECM remodeling may also be applied to valvulogenesis and congenital valve malformation. From here further research is needed to determine how findings in this study can be used to develop alternative therapeutic strategies to promote self-repair, replenishment and regeneration of valve cell populations in pathogenesis.
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###### 

Cell localization of Mmp3, Nid2 and Ptgs2 in the aortic valve at 4 months of age. Immunohistochemistry to show Mmp3 **(A)**, Nid2 **(B)** and Ptgs2 **(C)** expression (red) relative to CD31 (endothelial cells, green) in 4 month old aortic valve leaflets. Arrows indicate protein expression in VICs, arrowheads denote staining in CD31-positive VECs.
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